» Articles » PMID: 39468312

Baicalein Inhibits Cell Proliferation and Induces Apoptosis in Brain Glioma Cells by Downregulating the LGR4-EGFR Pathway

Overview
Date 2024 Oct 29
PMID 39468312
Authors
Affiliations
Soon will be listed here.
Abstract

Patients diagnosed with brain glioma have a poor prognosis and limited therapeutic options. LGR4 is overexpressed in brain glioma and involved in the tumorigenesis of many tumors. Baicalein (BAI) is a kind of flavonoid that has exhibited anti-tumor effects in various tumors. Nevertheless, the functions and associations of BAI and LGR4 in brain glioma remain unclear. In this study, Gene Expression Profiling Interactive Analysis and Human Protein Atlas databases were used to perform expression and survival analysis of LGR4 in brain glioma patients. Subsequently, the significance of LGR4-EGFR in brain glioma cells (HS683 and KNS89) and brain glioma animal models was explored by RNA interference and subcutaneous transplantation. Additionally, brain glioma cells were treated with BAI to explore the roles and mechanisms of BAI in brain glioma. The results showed that LGR4 was highly expressed in brain glioma and was related to a poor prognosis. LGR4 knockdown repressed the proliferation and EGFR phosphorylation but induced apoptosis in brain glioma cells. However, these effects were reversed by EGFR overexpression and CBL knockdown. In contrast, both in vitro and in vivo experiments revealed that LGR4 overexpression facilitated brain glioma cell malignant behavior and promoted tumor development, but these effects were rescued by BAI and an EGFR inhibitor. Furthermore, si-LGR4 accelerated EGFR protein degradation, while oe-LGR4 exhibited the opposite effect. Without affecting normal cellular viability, BAI inhibited malignant behavior, interacted with LGR4, and blocked the LGR4-EGFR pathway for brain glioma cells. In conclusion, our data suggested that BAI inhibited brain glioma cell proliferation and induced apoptosis by downregulating the LGR4-EGFR pathway, which provides a novel strategy and potential therapeutic targets to treat brain glioma.

References
1.
Daniels S, Liyasova M, Kales S, Nau M, Ryan P, Green J . Loss of function Cbl-c mutations in solid tumors. PLoS One. 2019; 14(7):e0219143. PMC: 6602201. DOI: 10.1371/journal.pone.0219143. View

2.
Liu Y, Zhang Y, Chen S, Zhong X, Liu Q . Effect of LGR4/EGFR signaling on cell growth and cancer stem cell-like characteristics in liver cancer. Cytokine. 2023; 165:156185. DOI: 10.1016/j.cyto.2023.156185. View

3.
Zhang Y, Li X, Yuan G, Hu H, Song X, Li J . β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G/M phase transition. J Biol Chem. 2017; 292(21):8933-8947. PMC: 5448126. DOI: 10.1074/jbc.M116.770420. View

4.
Tian J, Li J, Bie B, Sun J, Mu Y, Shi M . MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-κB signaling. Toxicol Appl Pharmacol. 2021; 420:115522. DOI: 10.1016/j.taap.2021.115522. View

5.
Huang R, Li G, Zhao Z, Zeng F, Zhang K, Liu Y . RGS16 promotes glioma progression and serves as a prognostic factor. CNS Neurosci Ther. 2020; 26(8):791-803. PMC: 7366748. DOI: 10.1111/cns.13382. View